Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026

Cancer’s Hidden Brake: How a Hormone Shields Tumors from Immune Attack
/in Immunotherapy, Preclinical Research/by MaxAZD0516: Phase 1 Trial for This STEAP2 ADC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Trial for Sacituzumab Tirumotecan and Tagitanlimab Combo
/in Clinical Trial, Metastatic, Phase 2/by MaxTJ101 Enters Testing for Advanced Prostate Cancer Patients
/in Clinical Trial, Metastatic, Phase 1/by MaxSpanish Study Confirms Real-World Success of Apalutamide in Prostate Cancer
/in Retrospective studies/by MaxFrom Proteins to Pathways: PDGrapher’s Shift in Drug Discovery
/in Artificial Intelligence/by MaxOST-504: A Novel Immunotherapy Targeting Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxMemantine Shows Promise Against Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by Max